skip to Main Content
April 26, 2017 1:00 - 2:00 PM ET

Drug Pricing: Where’s the Future Headed?

  • This page as PDF


Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.

Consumers rate drug prices as their primary concern in healthcare. Public focus on drug pricing is also amplified by the growth in spending on prescription drugs in Medicare and Medicaid. Policymakers, state governments, and private organizations have proposed policies to address drug prices that each carries their own set of implications.

Listen to Avalere experts Elizabeth Carpenter, Rujul Desai, and Caroline Pearson discuss potential drug pricing policy changes that seek to:

  • Increase transparency for pharmaceutical manufacturers and pharmacy benefit managers
  • Promote competition and market-based solutions
  • Medicaid reforms, including expansion funding and block grants/per-capita caps
  • Limit public program spending in Medicaid, Medicare Part D and Medicare Part B


Caroline Pearson formerly oversaw the firm’s content generation across consulting services, research products, and public visibility.
Elizabeth Carpenter , Head of Advisory Services

Elizabeth specializes in policy, particularly in the implementation of the Affordable Care Act (ACA), trends in commercial insurance, drug pricing policy, and the impact of politics on the policy landscape.

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Drug Pricing
Please enter your email address to be notified when new Drug Pricing insights are published.

Back To Top